Sirna, Dharmacon, Millennium Pharmaceuticals, CytRx, CombiMatrix, System Biosciences, Invitrogen, Qiagen, Epigenomics, RNAture | GenomeWeb

Sirna Plans Phase I Trial of Hep C Drug for Mid-2006

Sirna Therapeutics is in the process of planning primate studies of several formulations of siRNA-based drugs for hepatitis C, and expects to have chosen a candidate for phase I testing by mid-2006, according to President and CEO Howard Robin.

In January, former Sirna COO Nassim Usman told RNAi News that the company planned to test an HCV drug candidate in infected chimps, but would do so in collaboration with a partner given the difficulty of getting access to these animals.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.